SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is seeing strong community interest driven by its dominance on the Base network and anticipation surrounding a major multi-chain platform merger. Investors are actively discussing the protocol's liquidity-based buyback programs and potential for institutional growth, viewing recent price volatility as an accumulation opportunity ahead of upcoming product rollouts.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community debates its long-term potential as a decentralized AI infrastructure play, driven by strategic interest in its agentic AI technology and recent high-profile partnerships. While some investors remain cautious due to broader market volatility and Bitcoin's influence, others are aggressively accumulating, viewing the current price action as a significant discount before a projected shift in the AI narrative.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sony is trending as investors weigh the company's aggressive shift toward a high-margin, all-digital gaming model against community backlash regarding the potential phasing out of physical discs. Traders are also closely watching the firm's strategic pivot into 'physical AI' and robotics, viewing these as long-term growth catalysts alongside its core entertainment and image sensor divisions.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging as investor sentiment shifts due to clinical momentum and strong commercial performance, fueled by speculative buyout interest and an aggressive squeeze on a large short position. The community is actively discussing the stock's transition toward triple-digit valuation targets, with long-term shareholders closely monitoring for potential M&A catalysts.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T shares are currently trending downward as investors express concerns over potential long-term competition from SpaceX's Starlink satellite services in the wireless market. Despite the bearish sentiment, many community members remain bullish on the stock's valuation, highlighting its robust dividend yield and fiber infrastructure as a strong, undervalued buying opportunity.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors debate the impact of its recent research partnership with Honda and technical demonstrations with Ducati, with the community actively speculating on the stock's long-term commercialization path. Conversations are sharply divided between bulls citing the company's solid battery technology and OEM ecosystem, and bears expressing frustration over the lack of revenue and the time horizon for mass production.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group Holding Ltd (CRDO) is trending as investors react to its role as a critical connectivity bottleneck play in AI infrastructure, characterized by intense volatility and frequent institutional rebalancing. While community sentiment remains bullish on the company's long-term potential in data center optics and high-speed cabling, many are actively monitoring technical support levels and profit-taking patterns following a significant run-up.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is trending as investors digest its pivotal Phase 3 clinical trial results, while the broader biotech sector experiences significant momentum. Community discussion remains focused on the company's potential for FDA regulatory pathways, recent upsized capital offerings, and how its drug pipeline competes with established players in the mental health space.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Russell 2000 ETF (IWM) is seeing significant investor attention due to its recent record-high performance and a broader rotation of capital out of mega-cap tech into small-cap sectors. The community is actively debating the sustainability of this trend, with some traders highlighting the potential risks of a reversal if the current technical structure fails, while others are closely monitoring key support and resistance levels to gauge whether this marks a broader shift in market leadership.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is trending as investors rally around its v4 launch and a revenue-sharing model that distributes decentralized GPU network earnings to stakers. Community members are actively highlighting the high percentage of supply locked in long-term staking as a key driver of potential supply scarcity and sustained interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UnitedHealth Group Now Covers Guardant Healths Shield Blood Test for Colorectal Cancer Screening

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or...

GH Stock At Over 5-Year Highs – What’s The UnitedHealth Connection?

Equity

Effective August 1, UnitedHealth will begin offering insurance coverage for Guardant Health's colorectal cancer test.

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheims HERNEXEOS

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) for Boehringer Ingelheims HERNEXEOS (zongertinib tablets), the first targeted therapy for adults...

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid...

American Cancer Society Recommends Guardant Healths Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield...

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians...

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardants Board of Directors approved the granting of...

Guardant Health (GH) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of +4.60% and +8.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

Guardant Health Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.75	--	--	N/A
Q1 '26	-$0.81	-$0.85	-5.46%	MISSED
Q4 '25	-$0.77	-$1.00	-30.42%	MISSED
Q3 '25	-$0.79	-$0.74	6.28%	BEAT
Q2 '25	-$0.72	-$0.80	-11.72%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

GHGuardant Health Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest GH News